OriC613 / Oricell - LARVOL DELTA

MSLN and CLDN18.2 dual-target CAR-T therapy: Enhancing cancer treatment with improved efficacy and safety. (ASCO 2025) - "The remarkable anti-tumor effects and favorable safety of OriC613 stress the necessity of further clinical trials in patients suffering from pancreatic and gastric cancers."

Clinical • IO biomarker • Gastric Cancer • Hematological Malignancies • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • IFNG • IL2 • MSLN

Dual-target CAR-T strategy for MSLN and CLDN18.2: Advancing cancer treatment with superior efficacy and safety (AACR 2025) - "The impressive antitumor effects and promising safety of OriC613 highlight the need for continued clinical trials in pancreatic and gastric cancer patients."

Clinical • IO biomarker • Gastric Cancer • Hematological Malignancies • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • IFNG • MSLN

Yuanqi Biotech (Shanghai) Co., Ltd.'s drug clinical trial implied license application was accepted [Google translation] (163.com) - "On October 17, according to the official website of CDE, Yuanqi Biotech (Shanghai) Co., Ltd. jointly applied for the drug 'OriC613 Injection' and obtained implicit approval for clinical trials, acceptance number CXSL2400479....Public information shows that the drug 'OriC613 Injection' is indicated for advanced solid tumors."

New trial • Oncology • Solid Tumor

Enhanced antitumor efficacy and safety through a novel CAR-T strategy targeting MSLN and CLDN18.2 (ESMO-GI 2024) - "OriC613 exhibits strong antitumor efficacy and a promising safety profile. These results warrant further clinical trials of OriC613 in patients with pancreatic cancer and gastric cancer."

Clinical • IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • MSLN

ORIC-613, a potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models (AACR 2024) - "Oral dosing of ORIC-613 resulted in tumor growth inhibition and regressions in TRIM37 high xenograft breast tumors with no body weight loss. In summary, ORIC-613 is a potential first- and best-in-class development candidate, with exquisite selectivity for PLK4, which demonstrates synthetic lethality in TRIM37 high tumors and has the potential to benefit these patients."

Preclinical • Synthetic lethality • Breast Cancer • CNS Tumor • Neuroblastoma • Oncology • Oral Cancer • Solid Tumor • CASP3 • CASP7 • PLK4 • TRIM37

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "ORIC-613 is an orally bioavailable, potent and exquisitely selective small molecule inhibitor of PLK4, which is synthetic lethal in tumor cells with high levels of TRIM37....ORIC-613 has superior kinome selectivity versus comparator compounds CFI-400945 and RP-1664....Preclinical assessment in cancer cell lines revealed synthetic lethality, with ORIC-613 inducing apoptotic tumor cell death specifically in TRIM37-high breast cancer and neuroblastoma cells versus TRIM37-wildtype cells....Oral dosing of ORIC-613 at 150 mg/kg QD resulted in tumor regressions and tumor growth inhibition in TRIM37-high xenograft breast tumors."

Preclinical • Breast Cancer • Oncology • Solid Tumor